je.st
news
MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence
2014-09-08 02:29:34| Biotech - Topix.net
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that Columbia University and the New York State Psychiatric Institute was awarded new grant funding from the National Institute on Drug Abuse to continue clinical research on MN-166 in opioid dependence. The new grant will support the completion of a Phase 2a clinical trial of MN-166 in opioid dependence, for which positive interim results were previously reported by MediciNova on August 18, 2014.
Tags: grant
dependence
announces
opioid
Category:Biotechnology and Pharmaceuticals